Therefore, where is your data for men over 52 using HGH or Testosterone and their risk for cancer?
From http://www.biomedexp...ham_Morgentaler
- 2009: Isbarn Hendrik; Pinthus Jehonathan H; Marks Leonard S; Montorsi Francesco; Morales Alvaro; Morgentaler Abraham; Schulman Claude
Testosterone and prostate cancer: revisiting old paradigms.
European urology 2009;56(1):48-56. - 2009: Moreno Sergio A; Morgentaler Abraham
Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship.
The journal of sexual medicine 2009;6(6):1729-35. - 2009: Rosen Raymond C; Araujo Andre B; Connor Megan K; Elstad Emily A; McGraw Sarah A; Guay Andre T; Morgentaler Abraham; Miner Martin M
Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls.
The aging male : the official journal of the International Society for the Study of the Aging Male 2009;12(2-3):77-85. - 2009: Morgentaler Abraham
Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
The Journal of urology 2009;181(3):972-9. - 2009: Morgentaler Abraham
Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.
The journal of sexual medicine 2009;6(2):574-7. - 2009: Morgentaler Abraham; Traish Abdulmaged M
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
European urology 2009;55(2):310-20. - 2009: Morgentaler Abraham
Rapidly shifting concepts regarding androgens and prostate cancer.
TheScientificWorldJournal 2009;9():685-90. - 2009: Morgentaler Abraham; Schulman Claude
Testosterone and prostate safety.
Frontiers of hormone research 2009;37():197-203. - 2008: Morgentaler Abraham; Dobs Adrian S; Kaufman Joel M; Miner Martin M; Shabsigh Ridwan; Swerdloff Ronald S; Wang Christina
Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
The Journal of urology 2008;180(6):2307-13. - 2008: Dobs Adrian S; Morgentaler Abraham
Does testosterone therapy increase the risk of prostate cancer?
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2008;14(7):904-11. - 2008: Morgentaler Abraham
Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer.
The journal of sexual medicine 2008;5(8):1834-40. - 2008: Morgentaler Abraham
Re: effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
European urology 2008;53(5):1084. - 2008: Lazarou Stephen; Morgentaler Abraham
The effect of aging on spermatogenesis and pregnancy outcomes.
The Urologic clinics of North America 2008;35(2):331-9, xi. - 2008: Rhoden Ernani Luis; Riedner Charles Edison; Morgentaler Abraham
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
The Journal of urology 2008;179(5):1741-4; discussion 1744-5. - 2007: Morgentaler Abraham
Testosterone replacement therapy and prostate cancer.
The Urologic clinics of North America 2007;34(4):555-63, vii. - 2007: Reyes-Vallejo Luis; Lazarou Stephen; Morgentaler Abraham
Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
The journal of sexual medicine 2007;4(6):1757-62. - 2007: Crawford E David; Barqawi Al Baha; O'Donnell Colin; Morgentaler Abraham
The association of time of day and serum testosterone concentration in a large screening population.
BJU international 2007;100(3):509-13. - 2007: Morgentaler Abraham
Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship.
European urology 2007;52(3):623-5. - 2007: Morgentaler Abraham
Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80.
European urology 2007;52(1):292; author reply 293-4. - 2007: Mulhall John P; Morgentaler Abraham
Penile rehabilitation should become the norm for radical prostatectomy patients.
The journal of sexual medicine 2007;4(3):538-43. - 2007: Morgentaler Abraham
Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
The Journal of urology 2007;177(5):1954. - 2007: Morgentaler Abraham
New concepts regarding the relationship of testosterone and prostate cancer.
Future oncology (London, England) 2007;3(2):123-6. - 2007: Morgentaler Abraham
Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment.
The aging male : the official journal of the International Society for the Study of the Aging Male 2007;10(1):1-2. - 2007: Morgentaler Abraham
Commentary: Guideline for male testosterone therapy: a clinician's perspective.
The Journal of clinical endocrinology and metabolism 2007;92(2):416-7. - 2007: Lux Matthew; Reyes-Vallejo Luis; Morgentaler Abraham; Levine Laurence A
Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis.
The Journal of urology 2007;177(1):262-6. - 2006: Morgentaler Abraham; Rhoden Ernani Luis
Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Urology 2006;68(6):1263-7. - 2006: Lazarou Stephen; Reyes-Vallejo Luis; Morgentaler Abraham
Wide variability in laboratory reference values for serum testosterone.
The journal of sexual medicine 2006;3(6):1085-9. - 2006: Morgentaler Abraham
Testosterone and prostate cancer: an historical perspective on a modern myth.
European urology 2006;50(5):935-9. - 2006: Morgentaler Abraham
Testosterone therapy for men at risk for or with history of prostate cancer.
Current treatment options in oncology 2006;7(5):363-9. - 2006: Lazarou Stephen; Reyes-Vallejo Luis; Morgentaler Abraham
Phleboliths in varicoceles presenting as spermatic cord mass.
Fertility and sterility 2006;86(1):219.e21-2. - 2006: Morgentaler Abraham; Barada James; Niederberger Craig; Donatucci Craig; Garcia Carmen S; Natanegara Fanni; Ahuja Sanjeev; Wong David G
Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design.
The journal of sexual medicine 2006;3(3):492-503. - 2006: Morgentaler Abraham; Rhoden Ernani L; Barqawi Al Baha; Crawford E David
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
The Journal of urology 2006;175(4):1572; author reply 1573-4. - 2006: Reyes-Vallejo Luis; Lazarou Stephen; Morgentaler Abraham
Y chromosome microdeletions and male infertility: who should be tested and why?
BJU international 2006;97(3):441-3. - 2006: Rhoden E L; Morgentaler A
Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
International journal of impotence research 2006;18(2):201-5. - 2006: Morgentaler Abraham
Testosterone replacement therapy and prostate risks: where's the beef?
The Canadian journal of urology 2006;13 Suppl 1():40-3. - 2006: Lazarou Stephen; Reyes-Vallejo Luis; Morgentaler Abraham
Technical advances in penile prostheses.
Journal of long-term effects of medical implants 2006;16(3):235-47. - 2005: Lazarou Stephen; Morgentaler Abraham
Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
Current urology reports 2005;6(6):476-81. - 2005: Ramsawh Holly J; Morgentaler Abraham; Covino Nicholas; Barlow David H; DeWolf William C
Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1395-8. - 2005: Cady Blake; Barker Frederick; Easson Alexandra; Aboulafia Albert J; Ferson Peter F; Miner Thomas; Morgentaler Abraham
Part 3: surgical palliation of advanced illness: what's new, what's helpful.
Journal of the American College of Surgeons 2005;200(3):457-66. - 2005: Cady Blake; Miner Thomas; Morgentaler Abraham
Part 2: Surgical palliation of advanced illness: what's new, what's helpful.
Journal of the American College of Surgeons 2005;200(2):281-90. - 2004: Morgentaler Abraham
A 66-year-old man with sexual dysfunction.
JAMA : the journal of the American Medical Association 2004;291(24):2994-3003. - 2004: Rhoden E L; Morgentaler A
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
International journal of impotence research 2004;16(1):95-7. - 2004: Rhoden Ernani Luis; Morgentaler Abraham
Risks of testosterone-replacement therapy and recommendations for monitoring.
The New England journal of medicine 2004;350(5):482-92. - 2003: Rhoden Ernani Luis; Morgentaler Abraham
Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
The Journal of urology 2003;170(6 Pt 1):2348-51. - 2003: Rhoden Ernani Luis; Gobbi Daniel; Rhoden Claudia Ramos; Menti Eduardo; Roehe Adriane Nial; Hartmann Antonio; Morgentaler Abraham
Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats.
The Journal of urology 2003;170(5):2101-3. - 2003: Rhoden Ernani Luis; Estrada Carlos; Levine Laurence; Morgentaler Abraham
The value of pituitary magnetic resonance imaging in men with hypogonadism.
The Journal of urology 2003;170(3):795-8. - 2003: Rhoden Ernani Luis; Morgentaler Abraham
Erectile dysfunction.
Journal of long-term effects of medical implants 2003;13(6):519-28. - 2002: Yin Yizhong; Stahl Brandon C; DeWolf William C; Morgentaler Abraham
P53 and Fas are sequential mechanisms of testicular germ cell apoptosis.
Journal of andrology 2002;23(1):64-70. - 2001: Levine L A; Estrada C R; Morgentaler A
Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study.
The Journal of urology 2001;166(3):932-7. - 2000: Hoffman M A; DeWolf W C; Morgentaler A
Is low serum free testosterone a marker for high grade prostate cancer?
The Journal of urology 2000;163(3):824-7.